Dual effect of platelet lysate on human articular cartilage: a maintenance of chondrogenic potential and a transient proinflammatory activity followed by an inflammation resolution

Tissue Eng Part A. 2013 Jun;19(11-12):1476-88. doi: 10.1089/ten.TEA.2012.0225.

Abstract

Platelet-rich plasma (PRP), a cocktail of platelet growth factors and bioactive proteins, has been proposed as a therapeutic agent to restore damaged articular cartilage. We report the biological effect of the platelet lysate (PL), a PRP derivative, on primary human articular chondrocytes cultured under both physiological and inflammatory conditions. When added to the culture medium, PL induced a strong mitogenic response in the chondrocytes. The in vitro expanded cell population maintained a chondrogenic redifferentiation potential as revealed by micromass culture in vitro and ectopic cartilage formation in vivo. Further, in chondrocytes cultured in the presence of the proinflammatory cytokine interleukin-1α (IL-1α), the PL induced a drastic enhancement of the synthesis of the cytokines IL-6 and IL-8 and of neutrophil-gelatinase associated lipocalin, a lipocalin expressed during chondrocyte differentiation and inflammation. These events were mediated by the p38 MAP kinase and NF-κB pathways. We observed that inflammatory stimuli activated phospo-MAP kinase-activated protein kinase 2, a direct target of p38. The proinflammatory effect of the PL was a transient phenomenon; after an initial upregulation, we observed significant reduction of the NF-κB activity together with the repression of the inflammatory enzyme cyclooxygenase-2. Moreover, the medium of chondrocytes cultured in the simultaneous presence of PL and IL-1α, showed a significant enhancement of the chemoattractant activity versus untreated chondrocytes. Our findings support the concept that the platelet products have a direct beneficial effect on articular chondrocytes and could drive in sequence a transient activation and the resolution of the inflammatory process, thus providing a rational for their use as therapeutic agents in cartilage inflammation and damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Animals
  • Blood Platelets / chemistry*
  • Cartilage, Articular / drug effects*
  • Cartilage, Articular / enzymology
  • Cartilage, Articular / pathology*
  • Cell Differentiation / drug effects
  • Cell Differentiation / genetics
  • Cell Extracts / pharmacology*
  • Cell Lineage / drug effects
  • Cell Proliferation / drug effects
  • Cell Shape / drug effects
  • Cellular Microenvironment / drug effects
  • Cellular Microenvironment / genetics
  • Chemotaxis / drug effects
  • Chondrocytes / drug effects
  • Chondrocytes / metabolism
  • Chondrocytes / pathology
  • Chondrogenesis / drug effects*
  • Chondrogenesis / genetics
  • Culture Media, Conditioned / pharmacology
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 / metabolism
  • Cytokines / metabolism
  • Gene Expression Regulation / drug effects
  • Humans
  • Inflammation / genetics
  • Inflammation / pathology*
  • Inflammation Mediators / metabolism
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Mice
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Phosphorylation / drug effects
  • Protein Serine-Threonine Kinases / metabolism
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Cell Extracts
  • Culture Media, Conditioned
  • Cytokines
  • Inflammation Mediators
  • Intracellular Signaling Peptides and Proteins
  • NF-kappa B
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • MAP-kinase-activated kinase 2
  • Protein Serine-Threonine Kinases
  • p38 Mitogen-Activated Protein Kinases